Search
Sparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553]
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity
Moxisylyte
go.drugbank.com/drugs/DB09205Approved[T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA.
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalThe FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Lansoprazole
go.drugbank.com/drugs/DB00448ApprovedInvestigationalLansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective...
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the...
Tea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalTea tree oil is an essential oil derived mainly from the Australian native plant Melaleuca alternifolia via steam distillation of the of the leaves and terminal branches . It may be referred to as Melaleuca alternifolia oil. It has been ...